Spruce Q3 Loss Widens to $24M; Avenue Loan Amended, Adrenyx Spin Terms Set
SPRB sits 18% above its 52-week low of $38.06.
Summary
Spruce posted a $24.0M Q3 net loss as TA-ERT spending ramped, and disclosed an amended Avenue loan raising Tranche 2 to $15.0M plus terms for spinning CRHX-101 into Adrenyx with its own $10.0M note facility.
Key Events · Earnings and Guidance · SPRB
-
Q3 Loss Widens on TA-ERT Spend
Net loss was $24.0M, or $(8.51) per share, versus $8.2M a year ago; R&D rose to $18.1M from $5.0M on TA-ERT manufacturing and clinical development.
-
Cash Runway Into Second Half 2027
Cash and equivalents stood at $87.7M at September 30, 2026, up from $48.9M at December 31, 2025, which management says funds operations and debt obligations into the second half of 2027.
-
Avenue Loan Tranche 2 Raised to $15M
The November 6, 2026 amendment increases Tranche 2 to up to $15.0M drawable January 1–March 31, 2027, makes Tranche 3 discretionary, and extends the interest-only period through March 31, 2027 with options out to October 31, 2028.
-
Adrenyx Spin-Out Terms Disclosed
CRHX-101 was contributed to wholly-owned Adrenyx Biosciences on November 6, 2026; Adrenyx signed a convertible note facility of up to $10.0M with $5.0M funded at closing, and a private placement of up to $50M is expected alongside a pro rata distribution targeted for the first half of 2027.
Analysis · SPRB · Life Sciences
The quarter itself is a cash-burn story: R&D jumped to $18.1M from $5.0M a year ago as TA-ERT manufacturing and clinical work ramps, pushing the net loss to $24.0M. What matters more is the financing scaffolding around it. The Avenue amendment lifts Tranche 2 to $15.0M and pushes the interest-only period out to March 2027, with two further extension options — breathing room while the December 2026 BLA goes in. The Adrenyx separation moves CRHX-101 off Spruce's books with its own $10.0M convertible note facility ($5.0M already funded) and a planned up-to-$50M private placement, so Spruce's cash is reserved for TA-ERT. Cash of $87.7M is stated to fund operations and debt into the second half of 2027, which covers the BLA submission but not a commercial launch without more capital.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 36.6% of the 2965 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SPRB was trading at $45.07 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $133.8M. The 52-week trading range was $38.06 to $129.00. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.